New Mexico, USA 01/01/2013 – Indica Labs, Inc. announced today the release of a revolutionary molecular pathology software module for automated analysis of fluorescent RNA In situ Hybridization (RNA ISH) assays. This latest software application is the first of its kind, offeringwhole-slide quantification of multiplexed RNA biomarkers on a cell-by-cell basis. The software rapidly generates single-cell RNA expression profiles for hundreds of thousands of cells in microscopic fluorescent images, allowing researchers to precisely measure overall expression ratios and cellular heterogeneity across entire tissue sections, tissue microarrays, and other microscope slide-based applications.

Molecular RNA assays have moved increasingly to the mainstream for major biomedical research areas including oncology and neuroscience. More recently, advancements have been made by the introduction of chromogenic RNA ISH for brightfield interpretation and multiplex RNA FISH for measuring multiple RNA biomarkers simultaneously. Until now there has been a lack of software for truecell-based quantification of these new multiplex assays. Indica has developed the Multiplex RNA FISH software for assays like RNAscope®, an award-winningmultiplex single-molecule RNA ISH technology developed by Advanced Cell Diagnostics (Hayward, California). ACD CEO Yuling Luo, PhD. remarked “Multiplex quantitative analysis of gene expression in single cells while preserving cellular context is very important in today’s biomedical research and molecular diagnostics. It should greatly facilitate the study of cellular heterogeneity that underlies nearly all of the biological and disease processes”.

Indica’s Multiplex RNA FISH module combined with their Chromogenic RNA ISH module and HALO™ platform have propelled Indica Labs’ leadership with the most advanced software technologies for molecular pathology image analysis. Indica CEO, Steven Hashagen commented “With the release of this software, Indica Labs offers the most complete RNA ISH quantification suite for both brightfield and fluorescence; meanwhile we have a number of exciting related technologies in development.”

For more information please click here or


About Advanced Cell Diagnostics

Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research tools for all areas of biomedical research, and diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the most sensitive method available for RNA ISH, and the first quantitative and fully automated platform enabling multiplex fluorescent and chromogenic RNA biomarker analysis. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases. These partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at



Scroll to Top